Aurobindo Pharma is currently trading at Rs. 1373.20, up by 14.30 points or 1.05% from its previous closing of Rs. 1358.90 on the BSE.
The scrip opened at Rs. 1362.40 and has touched a high and low of Rs. 1380.00 and Rs. 1360.15 respectively. So far 26998 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1432.10 on 17-Apr-2015 and a 52 week low of Rs. 644.65 on 10-Jul-2014.
Last one week high and low of the scrip stood at Rs. 1380.00 and Rs. 1270.10 respectively. The current market cap of the company is Rs. 39826.38 crore.
The promoters holding in the company stood at 53.97% while Institutions and Non-Institutions held 35.82% and 10.21% respectively.
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Entacapone Tablets USP, 200mg (ANDA 203437). The product will be launched soon. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Comtan Tablets 200mg of Orion Corporation.
Entacapone Tablets are used in the treatment of Parkinson's disease and has an estimated market size of $59 Million for the twelve months ending April 2015 according to IMS. This is the 39th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.60 |
| Dr. Reddys Lab | 1237.20 |
| Cipla | 1235.85 |
| Zydus Lifesciences | 941.30 |
| Lupin | 2323.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: